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History of Myology in Italy and its international 
collections
C. Angelini
University of Padova, Italy
The history of Myology in Italy begins in 16th century with 
muscle anatomy pictures by Vesalius and Canani while in the 
19th century the Neapolitan physician Gaetano Conte described 
Duchenne muscular dystrophy on clinical basis (1).
Myology reached a major development in the 20th century 
with the establishment of the CNR center in Padova (professor 
Massimiliano Aloisi) a cardiomyological and genetic center in 
Naples (professor Giovanni Nigro) and a neurological center in 
Milan (professor Guglielmo Scarlato). In the 60th prof. Aloisi and 
Federico Milcovich, a myodystrophic patient, started the Italian 
Muscular Dystrophy patients association (UILDM) with contacts 
with MDA (2). The first congress in Neuromuscular diseases took 
place in Milan in 1969 by the organization of professor Scarlato, 
Aloisi, Canal and was attended by several outstanding internation-
al muscle researchers such as AG Engel, WK Engel, LP Rowland, 
M.Fardeau and I.Hausmanowa-Petrusewicz. Eleven meetings in 
many countries followed this, up to the last XII international Con-
gress on Neuromuscular Diseases in Naples in 2010.
Several laboratories arose in the country especially in Neu-
rological Institutes; several researchers emigrated permanently 
or went for a stage to improve their myological skills especially 
in USA, UK, Canada, France both in basic and/or pathological, 
clinical research (Table 1). The laboratory of Columbia in New 
York, lead by professor Di Mauro was a common place of train-
ing especially in the field of mitochondrial myopathies.
As in other developed countries, the basis of neuromuscular 
research and diagnosis were expanded on immunohistochemi-
cal, biochemical and molecular grounds, during the 20th and the 
beginning of the 21st century. Enzo Ferrari – a race car factory 
engineer – was a support to research in muscular dystrophy in 
Milan, Padova and Modena. Telethon has contributed to sup-
port in neuromuscular disorders. Myology with the enlargement 
of scientific basis in the molecular era began to split in sub-
specialities i.e. genetics, physiopathology etc. and a spectrum of 
knowledge was accumulated both for diagnostic and therapeu-
tic purposes. In the field of metabolic diseases and limb-girdle 
myopathies several Italian laboratories described new entities. 
A number of treatments, beside the treatment of inflammatory 
myopathies and myasthenia gravis, were found and applied in 
metabolic myopathies: i.e. carnitine, Coenzyme Q, enzyme re-
placement in glycogenosis type II.
The continuous challenge of the treatment of the primary 
muscular dystrophy remains for the future since so far there are 
only emerging molecular therapies: antisense oligonucleotides 
in DMD, adenoviral therapy in sarcoglycanopathies, cell therapy 
might contribute to answer to a promises for muscular patients.
In the translation area many laboratories and Italian groups 
continue  with  new  researchers  and  they  have  contributed  to 
meetings of European Neuromuscular Center and to the Foun-
dation and organisation of the World Muscle Society with meet-
ings in Italy (Naples, Taormina), and to the Treat – NMD and 
Eurobiobank networks.
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Can we bypass a muscle metabolic defect?
Z. Argov
Department  of  Neurology,  Hadassah-Hebrew  University  Medical 
Center, Jerusalem, Israel
The metabolic myopathies are thought to be more amena-
ble to treatment once the defect in the biochemical pass way is 
identified. Some of the defects cause mainly exercise intoler-
ance and its improvement can be regarded as therapeutic suc-
cess. In others muscle weakness and degeneration is seen and 
functional and strength improvement is the goal.
Therapy  of  such  muscle  metabolic  disorders  can  be 
achieved  through  enzyme  replacement,  e.g.  therapy  of  acid 
maltase deficiency (Pompe’s disease) which is currently admin-
istered to young and adult patients. Enzyme upregulation can 
also be attempted and a case in point is bezafibrate in carnitine 
palmityl transferase 2 deficiency.
Lectures by invited speakers
Table 1. The main international connections.
USA - Mayo Clinic (Engel AG): Angelini, Mora, Milone, 
Fumagalli
USA - Children Hospital (Hoffmann): Pegoraro, Gorni
USA - USC Los Angeles (Engel WK, Askanas): Martinuzzi, 
Vita, Broccolini, Mirabella, Vattemi
USA - Columbia University (Rowland, Di Mauro): Trevisan, 
Bresolin, Bruno, Mancuso, Zeviani, Servidei, Ricci, Minetti, 
Moggio, Musumeci, Salviati.
Canada - Montreal (Karpati): Armani
UK - London (Dubowitz): Muntoni, Mercuri, Sorarù
UK - London (Morgan-Hughes): Toscano
UK - Newcastle (Walton, Bushby): Vita, Guglieri
UK - Oxford (Vincent): Evoli
UK - Liverpool (Edwards): Siciliano
France - Paris (Fardeau, Tomè): Villanova, Berardinelli
France - Nice (Desnuelle): Sacconi
France - Poitiers (Rideau): Nigro, Comi, Politano, Bianchi
Poland –Warsaw (Hausmanowa-Petrusewicz): (Nigro, Comi, 
Petretta, Politano)152
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Other  potential  modes  of  metabolic  therapy  include: 
1.Supplementation of the missing compound, e.g. CoQ10 which 
is effective only in primary Q10 deficiency and is given to most 
patients with mitochondrial disorders even if deficiency is not 
tested; 2. Pharmacologically increasing the oxidative capacity 
of muscle (by giving various ‘cocktails’ of oxygen species scav-
engers that include: carnitine, vitamin C, riboflavin, and extra 
creatine); 3. Changing the diet composition in order to increase 
the availability of compensatory fuel sources (e.g. sucrose or a 
carbohydrate rich diet given before exercise in MacArdle’s dis-
ease). Because of the rarity of metabolic myopathies no proper 
double blind studies were performed to assess these therapeutic 
modalities.
Hereditary inclusion body myopathy (HIBM) is a destruc-
tive muscle disease due to mutations in GNE, an enzyme in the 
synthetic pathway of sialic acid. Part of the pathogenic mecha-
nism is thought to be sialylation deficiency so correcting it may 
affect the disease course. Providing orally a metabolic interme-
diate that is downstream to the defective site in the sialic acid 
pathway (e.g. ManNac) or sialic acid itself was shown to be ef-
fective in a mouse model of HIBM. With these considerations in 
mind, planned therapy of this progressive metabolic myopathy 
is now reaching human trials. Human and animal toxicity stud-
ies with various compounds are now in progress.
I-3
Treatment of CPT2 deficiency with bezafibrate
P. Laforet
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Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, 
Paris, France
The most prevalent fatty acid oxidation disorders (FAO) in 
adults are carnitine palmitoyl transferase II (CPTII), very-long 
chain Acyl-CoA-dehydrogenase (VLCAD) and multiple Acyl-
Coa dehydrogenase (MAD) deficiencies.
Proposed  treatment  strategies  for  FAO  defects  include 
avoidance of exacerbating factors, carnitine supplementation, 
riboflavin treatment and dietary modifications (medium-chain 
triglycerides and triheptanoin). Riboflavin treatment may in-
duce  a  dramatic  improvement  of  muscle  symptoms  and  en-
cephalopathy in some patients with riboflavin-responsive MAD 
deficiency.
Children with long-chain FAO defects are generally treat-
ed with a low long-chain fat diet and supplements of MCT, 
but  the  evidence  for  benefit  is  less  convincing  in  patients 
whose problems are recurrent rhabdomyolysis. A remarkable 
improvement of cardiac and muscular symptoms occurred in 
three children with VLCAD deficiency and in seven patients 
with CPTII deficiency after dietary supplementation with tri-
heptanoin,  a  seven-carbon  medium-chain  fatty  acid,  which 
supposed mechanisms are the production of C5 ketone bodies 
and propionyl-CoA, allowing to replenish the pool of catalytic 
intermediates of the citric acid cycle. Further clinical trials and 
prolonged clinical follow-up are needed to confirm the benefit 
of these treatments.
A recently tested alternative way to treat FAO disorders 
are  agonists  of  peroxisome  proliferators-activated  receptors 
(PPARs), that are potent pharmaceutical tools stimulating FAO 
enzymes in a wide variety of cells. Recent data showed in vivo 
correction of CPT II and VLCAD deficiency in cultured pa-
tients’ fibroblasts, with bezafibrate a widely prescribed hypolip-
idemic drug. The potential for bezafibrate to correct inborn FAO 
disorders, has already conducted to the achievement of a pilot 
clinical trial in 6 adults with CPT II deficiency showing a clear 
improvement of FAO in muscle.
Another potential target for improving FAO oxidation is 
AMP-activated protein kinase (AMPK). Exercise, some drugs 
(metformine, rosiglitazone), and hormones such as leptin and 
adiponectine are known activators of AMPK in skeletal muscle 
and increase FAO in muscle. The development of new drugs 
modulating the activity of AMPK could also open new avenues 
for the treatment of FAO disorders.
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Long-term follow-up effects on enzyme 
replacement treatment of adult form of acid 
maltase deficiency myopathy
C. Angelini1, C. Semplicini, S. Ravaglia, B. Bembi, 
S. Servidei, M. Moggio, M. Filosto, E. Sette, E. Pegoraro, 
G. Crescimanno, P. Tonin, R. Parini, L. Morandi, G. Marrosu, 
G. Greco, O. Musumeci, G. Di Iorio, G. Siciliano, M.A. 
Donati, T. Mongini1, A. Toscano1, and the Italian GSDII 
Group (L. Vercelli, R. di Giacopo, V. Lucchini, V. Tugnoli, 
M. Rigoldi, R. Piras, F. Giannini, S. Gasperini, L. Volpi, 
D. Diodato, A. Ariatti)
1 Coordinators of the Italian Group on GSDII, University of Padova, 
Torino and Messina, Italy
We evaluated the clinical efficacy of alglucosidase alpha 
enzyme replacement therapy (ERT) in 77 patients with late-on-
set glycogen storage disease type 2 (GSDII) at various stages of 
disease progression. Previous studies on efficacy led to demon-
strate ERT efficacy against placebo in a 18 months study (LO-
TOS van Der Ploeg, NEJM, 2010).
Seventy-seven juvenile or adult patients were treated with 
ERT in a multi-centre open label non-randomized study with 
regular clinical assessment for up to 54 months. Recombinant 
human alpha glucosidase (rh-GAA) was injected by intrave-
nous route at 20 mg/kg i.v. every second week. For analysis, 
patients were divided in three groups: one group received ERT 
treatment  for  12-18  months,  a  second  group  received  ERT 
treatment for 24-30 months, and a third group patients were 
treated for over 36 months. Clinical assessment included a 
6-minute walk test (6MWT), the Walton and Gardner-Medwin 
scale, forced vital capacity (FVC) and blood creatine kinase 
(CK). All tests were performed at baseline and every three 
months thereafter.
ERT was associated with a longer walking distance on the 
6MWT. FVC was stabilized in most patients, and a significant 
decrease in number of hours off the ventilator was found in sev-
eral patients. Few adverse effects were observed, leading to dis-
continuation of treatment in 1 patient.
ERT appears a long term reasonable safe treatment for all 
patients examined. The response pattern in a single patient was 
variable and not always correlated with treatment duration.